Mostrando 10 resultados de: 86
Filtros aplicados
Publisher
Pharmacogenomics(16)
Pharmacogenomics Journal(15)
Drug Metabolism and Drug Interactions(7)
European Journal of Clinical Pharmacology(7)
Molecular Psychiatry(3)
Área temáticas
Farmacología y terapéutica(65)
Enfermedades(46)
Bioquímica(28)
Fisiología humana(14)
Genética y evolución(11)
Área de conocimiento
Farmacología(51)
Genética(41)
Psicopatología(11)
Medicamento(6)
Trastorno depresivo mayor(4)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(84)
ODS 10: Reducción de las desigualdades(66)
ODS 17: Alianzas para lograr los objetivos(53)
ODS 9: Industria, innovación e infraestructura(27)
ODS 12: Producción y consumo responsables(10)
Origen
google(5)
Eating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusThe role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions
ReviewAbstract: In the recent years it has been increasingly recognized that pharmacogenetical factors play an imporPalabras claves:CYP2D6, CYP3A4, metabolism, pharmacogenetics, RisperidoneAutores:Adrián LLerena, Berecz R., Cáceres M.C., De la Rubia A., Degrell I., Dorado P.Fuentes:scopusThioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
ArticleAbstract: Background: Approximately 7% of Caucasians have genetically impaired activity of the cytochrome P450Palabras claves:Cytochrome p450, pharmacogenetics, smoking, ThioridazineAutores:Adrián LLerena, Berecz R., Dahl M.L., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopusStudy of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards
ArticleAbstract: BACKGROUND AND OBJECTIVE: CYP2D6 metabolic capacity shows genetic polymorphism. Two metabolic phenotPalabras claves:Cubans, CYP2D6, debrisoquine, Hispanics, Interethnic variability, pharmacogenetics, Phenotype, SpaniardsAutores:Adrián LLerena, Alvárez M., Dorado P., González I., Pérez B.Fuentes:scopusUse of pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6
ArticleAbstract: In bioequivalence studies, intra-individual variability (CV w) is critical in determining sample sizPalabras claves:bioequivalence, Cost, CYP2D6, Genotypes, intra-individual, variabilityAutores:Abad-Santos F., Adrián LLerena, Carcas-Sansuan A., Dorado P., Estévez-Carrizo F.E., González-Vacarezza N., Penãs-Lledó E.M.Fuentes:scopusAssociation between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
ArticleAbstract: Background: An involvement of serotonin receptor 2A (5-HT2A) in the aetiology of schizophrenia has bPalabras claves:A-1438G polymorphism, Risperidone, Schizophrenia, Seretonin 2A receptor, T102C polymorphismAutores:Adrián LLerena, Cáceres M.C., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAssociation of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
ArticleAbstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in paPalabras claves:Adverse events, Antipsychotic, pharmacogenetics, RisperidoneAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusCYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
ArticleAbstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in CaPalabras claves:CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogeneticsAutores:Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., LARES, Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.Fuentes:scopusCYP2C9 gene and susceptibility to major depressive disorder
ArticleAbstract: Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disPalabras claves:CYP2C9 gene, Depression, SchizophreniaAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopus